John Rawls' theory and the fairness of Supreme Federal Court decisions in high-cost drug claims

Autores

  • Luis Augusto Teixeira Morais
  • Cristina Godoy Bernardo de Oliveira

DOI:

https://doi.org/10.12957/rqi.2021.63005

Palavras-chave:

Health Law. Judicial Decisions. John Rawls. Federal Supreme Court. Theory of Justice

Resumo

Based on the Theory of Justice of John Rawls, this article analyses justice regarding the decisions of the Federal Supreme Court of Brazil (STF) related to public concessions of expensive medicines. This study focuses on constitutional principles like the universality and integrality in health care illuminated by the minimum existential and the reserve for contingencies. The study of the decisions of the Federal Supreme Court searched an equity approach and the consequences for the poor that depends on the public health system (SUS) to receive health care. Applying the analytical and synthetic methods, the analyses showed that the decisions are not fair in the same way John Rawls argues that because there is no protection of the minimum existential. Thus, there is a health injury to the poor that could be avoided by the theory of justice of John Rawls.

 

Biografia do Autor

Luis Augusto Teixeira Morais

Mestre em Direito pela Faculdade de Direito de Ribeirão Preto da Universidade de São Paulo (2019). Advogado. 

 

Cristina Godoy Bernardo de Oliveira

Doutora em Filosofia do Direito pela Faculdade de Direito da Universidade de São Paulo (2011). Professora Doutora da Faculdade de Direito da Universidade de São Paulo - Campus Ribeirão Preto desde 2011. Pós-Doutorado em Filosofia do Direito pela Université Paris I - Panthéon/Sorbonne (Agosto/2014 - Dezembro/2015) com vínculo ao Instituto NoSoPhi. Academic Visitor da Faculty of Law - Oxford University onde está desenvolvendo o projeto de pesquisa concernente à Propriedade Intelectual (2015-2016).

 

Downloads

Como Citar

Morais, L. A. T., & Oliveira, C. G. B. de. (2021). John Rawls’ theory and the fairness of Supreme Federal Court decisions in high-cost drug claims. REVISTA QUAESTIO IURIS, 14(03), 1334–1369. https://doi.org/10.12957/rqi.2021.63005